Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $44.22

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has received a consensus rating of "Buy" from the ten analysts that are presently covering the stock, MarketBeat.com reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have covered the stock in the last year is $44.22.

FDMT has been the topic of several recent research reports. Barclays began coverage on 4D Molecular Therapeutics in a report on Monday, April 15th. They set an "overweight" rating on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, March 1st. Royal Bank of Canada increased their target price on shares of 4D Molecular Therapeutics from $35.00 to $40.00 and gave the company an "outperform" rating in a research report on Monday, April 15th. BMO Capital Markets dropped their price target on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an "outperform" rating on the stock in a research report on Monday, April 1st. Finally, Jefferies Financial Group boosted their target price on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a "buy" rating in a report on Monday, April 1st.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT traded down $0.28 during mid-day trading on Friday, hitting $23.25. 322,774 shares of the stock traded hands, compared to its average volume of 1,032,310. 4D Molecular Therapeutics has a twelve month low of $9.44 and a twelve month high of $36.25. The company has a market cap of $1.19 billion, a PE ratio of -8.85 and a beta of 2.87. The firm has a 50 day simple moving average of $28.68 and a two-hundred day simple moving average of $20.57.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.09). 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 34.14%. The firm had revenue of ($0.02) million for the quarter, compared to analyst estimates of $4.67 million. On average, equities research analysts anticipate that 4D Molecular Therapeutics will post -3.03 earnings per share for the current fiscal year.

Insider Activity

In other 4D Molecular Therapeutics news, insider Robert Young Kim sold 24,552 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $30.05, for a total value of $737,787.60. Following the transaction, the insider now owns 1,043 shares in the company, valued at $31,342.15. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other 4D Molecular Therapeutics news, insider Robert Young Kim sold 24,552 shares of the business's stock in a transaction on Monday, February 5th. The shares were sold at an average price of $30.05, for a total transaction of $737,787.60. Following the completion of the sale, the insider now owns 1,043 shares in the company, valued at approximately $31,342.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Scott Bizily sold 6,244 shares of the firm's stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $27.50, for a total transaction of $171,710.00. Following the completion of the transaction, the insider now directly owns 1,737 shares in the company, valued at $47,767.50. The disclosure for this sale can be found here. Insiders sold a total of 143,942 shares of company stock worth $4,074,435 in the last three months. Company insiders own 10.70% of the company's stock.

Institutional Trading of 4D Molecular Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Bfsg LLC purchased a new stake in shares of 4D Molecular Therapeutics in the fourth quarter worth approximately $30,000. Allspring Global Investments Holdings LLC raised its stake in shares of 4D Molecular Therapeutics by 702.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company's stock worth $110,000 after purchasing an additional 3,026 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of 4D Molecular Therapeutics by 359.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,951 shares of the company's stock worth $100,000 after purchasing an additional 3,873 shares during the last quarter. Daiwa Securities Group Inc. raised its stake in shares of 4D Molecular Therapeutics by 23.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,872 shares of the company's stock worth $119,000 after purchasing an additional 1,110 shares during the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in shares of 4D Molecular Therapeutics in the third quarter worth approximately $141,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.